Does non-antiarrhythmic pharmacotherapy reduce incident atrial fibrillation in patients with cardio-renal-metabolic disease?
The authors call for future trials of cardio-renal-metabolic medications to include incident atrial fibrillation as a pre-specified outcome.
Prospective RCTs with AF as a pre-specified outcome should be integrated into the design of future trials of cardio-renal-metabolic medications to determine whether they reduce incident AF.
“Available data provide hypothesis-generating estimates that treatment of HFrEF with ACEi/ARB, MRA, and SGLT2 inhibitors, treatment of CKD with SGLT2 inhibitors, and treatment of obesity with GLP-1 RAs, may be associated with a relative risk reduction in incident AF.”
Raveendra et al. (Fri,) studied this question.